Elite Pharmaceuticals, Inc.
ELTP
$0.53
$0.010.95%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 92.38% | 113.85% | 78.26% | -7.56% | 33.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 92.38% | 113.85% | 78.26% | -7.56% | 33.36% |
| Cost of Revenue | 108.26% | 25.72% | 49.54% | -2.97% | 38.56% |
| Gross Profit | 71.68% | 221.26% | 113.04% | -13.09% | 27.15% |
| SG&A Expenses | 75.36% | 70.98% | -8.93% | 58.72% | 47.60% |
| Depreciation & Amortization | -6.04% | -7.24% | 7.61% | 25.91% | 28.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.57% | 23.91% | 35.29% | 10.50% | 25.86% |
| Operating Income | 135.69% | 461.57% | 242.14% | -68.92% | 80.99% |
| Income Before Tax | 264.83% | -166.55% | 866.79% | -11,196.71% | -248.32% |
| Income Tax Expenses | 31.02% | 2,193.32% | 270.67% | 129.88% | 108.59% |
| Earnings from Continuing Operations | 224.16% | -1,055.62% | 411.07% | -1,641.89% | -173.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 224.16% | -1,055.62% | 411.07% | -1,641.89% | -173.90% |
| EBIT | 135.69% | 461.57% | 242.14% | -68.92% | 80.99% |
| EBITDA | 120.43% | 415.05% | 221.42% | -60.52% | 73.36% |
| EPS Basic | 224.27% | -1,016.67% | 381.82% | -1,557.14% | -170.07% |
| Normalized Basic EPS | 262.50% | -160.00% | 916.67% | -463.64% | -229.41% |
| EPS Diluted | 152.43% | -1,766.67% | 15,800.00% | -1,557.14% | -203.00% |
| Normalized Diluted EPS | 253.57% | -160.00% | 916.67% | -463.64% | -229.41% |
| Average Basic Shares Outstanding | 0.34% | 0.01% | 4.84% | 5.27% | 5.36% |
| Average Diluted Shares Outstanding | 6.86% | -0.73% | 3.28% | 4.28% | 4.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |